PARIS — Adding the PCSK9 inhibitor evolocumab (Repatha, Amgen) to high-intensity statin therapy in the very high-risk setting of acute coronary syndrome (ACS) safely lowers low-density lipoprotein ...

LONDON, England—Aggressive cholesterol lowering at the time of hospitalization for MI results in better clinical outcomes at 1 year when compared with the current stepwise treatment strategy, ...

If you have high cholesterol, there's a good chance your doctor has recommended statins to get your numbers back into a healthier range and reduce the risk of heart attack and stroke. But what's the ...

In a recent study published in JAMA, researchers investigated whether treat-to-target (TTT) low-density lipoprotein-cholesterol (LDL-C) therapy was inferior to administering statins of high intensity ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr. Charles Hennekens, a medical school professor and heart disease researcher at Florida Atlantic University in Boca Raton, Fla., ...

CHICAGO, IL—A decision-support tool failed to significantly increase the use of combination therapy or intensification of current lipid-lowering regimens compared with usual care in patients recently ...

Statins are among the most commonly prescribed medications for reducing high cholesterol and lowering the risk of heart attack and stroke. People searching for popular statin medications are often ...

Please provide your email address to receive an email when new articles are posted on . A treat-to-target statin strategy was noninferior to a high-intensity statin strategy in CAD. The data highlight ...

Research at the European Society of Cardiology Congress 2024 evaluated lipid-lowering therapy beyond statins alone in patients with high levels of low-density lipoprotein cholesterol. While statins ...

The debate continues as to whether or not statins have effects other than those that lower lipids that may provide additional cardiovascular benefits. An array of proposed pleiotropic effects have ...